Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 31/5/2020
SIETES contiene 93020 citas

 
 
 1 a 20 de 34 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby J-F, Tricoci P, White HD, Zeiher AM, for the ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med 2018;379:29 de noviembre. [Ref.ID 102917]
2.Enlace a cita originalTiene citas relacionadas
Rodríguez F, Harrington RA. Cholesterol, cardiovascular risk, statins, PCSK9 inhibitors, and the future of LDL-C lowering. JAMA 2016;316:1967-8. [Ref.ID 100983]
3. Cita con resumen
Cohen AT, Harrington RA, Goldhaber SZ, Hull RD, Wiens BL, Gold A, Hernandez AF, Gibson CM, for the APEX Investigators. Extended thromboprophylaxis with betrixaban in acutely ill medical patients. N Engl J Med 2016;375:534-44. [Ref.ID 100706]
4.Tiene citas relacionadas Cita con resumen
Steg PG, Bhatt DL, Hamm CW, Stone GW, Gibson CM, Mahaffey KW, Leonardi S, Liu T, Skerjanec S, Day JR, Iwaoka RS, Stuckey TD, Gogia HS, Gruberg L, French WJ, White HD, Harrington RA, for the CHAMPION Investigators. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Lancet 2013;382:1981-92. [Ref.ID 96671]
5.Tiene citas relacionadas
Bhatt DL, Harrington RA, for the CHAMPION PHOENIX Executive Committee and Investigators. Platelet inhibition with cangrelor during PCI. The authors reply. N Engl J Med 2013;369:393-4. [Ref.ID 95884]
6.Tiene citas relacionadas Cita con resumen
Califf RM, McCall J, Harrington RA. Assessing research results in the medical literature: trust but verify. JAMA Intern Med 2013;173:1053-5. [Ref.ID 95719]
7.Tiene citas relacionadas Cita con resumen
Bhatt DL, Stone GW, Mahaffey KW, Gibson CM, Steg G, Hamm CW, Price MJ, Leonardi S, Gallup D, Bramucci E, Radke PW, Widimsky P, Tousek F, Tauth J, Spriggs D, McLaurin BT, Angiolillo DJ, Généreux P, Liu T, Prats J, Todd M, Skerjanec S, White HD, Harrington RA, for the CHAMPION PHOENIX Investigators. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med 2013;368:1303-13. [Ref.ID 95246]
8.
Tricoci P, Huang Z, Held C, Moliterno DJ, Armstrong PW, Van de Werf F, White HD, Aylward PE, Wallentin L, Chen E, Lokhnygina Y, Pei J, Leonardi S, Rorick TL, Kilian AM, Jennings LHK, Ambrosio G, Bode C, Cequier A, Cornel JH, Diaz R, Erkan A, Huber K, Hudson MP, Jiang L, Jukema JW, Lewis BS, Lincoff AM, Montalescot G, Nicolau JC, Ogawa H, Pfisterer M, Prieto JC, Ruzyllo W, Sinnaeve PR, Storey RF, Valgimigli M, Whellan DJ, Widimsky P, Strony J, Harrington RA, Mahaffey KW, for the TRACER Investigators. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med 2012;366:20-33. [Ref.ID 92104]
9.Tiene citas relacionadas Cita con resumen
Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P, Bhatt DL, Goodman S, Verheugt FW, Flather M, Huber K, Liaw D, Husted SE, Lopez-Sendon J, De Caterina R, Jansky P, Darius H, Vinereanu D, Cornel JH, Cools F, Atar D, Leiva-Pons JL, Keltai M, Ogawa H, Pais P, Parkhomenko A, Ruzyllo W, Diaz R, White H, Ruda M, Geraldes M, Lawrence J, Harrington RA, Wallentin L, for the APPRAISE-2 Investigators. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011;365:699-708. [Ref.ID 91101]
10.
James SK, Roe MT, Cannon CP, Cornel JH, Horrow J, Husted S, Katus H, Morais J, Steg PG, Storey RF, Stevens S, Wallentin L, Harrington RA, for the PLATO Study Group. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO. BMJ 2011;342:1403. [Ref.ID 90953]
11.Tiene citas relacionadas Cita con resumen
Najjar SS, Rao SV, Melloni C, Raman SV, Povsic TJ, Melton L, Barsness GW, Prather K, Heitner JF, Kilaru R, Gruberg L, Hasselblad V, Greenbaum AB, Patel M, Kim RJ, Talan M, Ferrucci L, Longo DL, Lakatta EG, Harrington RA, for the REVEAL Investigators. Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction. REVEAL: a randomized controlled trial. JAMA 2011;305:1863-72. [Ref.ID 90794]
12.Tiene citas relacionadas
Bhatt DL, Harrington RA. Platelet inhibition with cangrelor. The authors reply. N Engl J Med 2010;362:1049. [Ref.ID 88078]
13.Tiene citas relacionadas Cita con resumen
Cannon CP, Harrington RA, James S, Ardissino D, Becker RC, Emanuelsson H, Husted S, Katus H, Keltai M, Khurmi NS, Kontny F, Lewis BS, Steg PG, Storey RF, Wojdyla D, Wallentin L, for the PLATelet inhibition and patient Outcomes (PLATO) investigators. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet 2010;375:283-93. [Ref.ID 87547]
14.Tiene citas relacionadas Cita con resumen
Harrington RA, Stone GW, McNulty S, White HD, Lincoff AM, Gibson CM, Pollack Jr CV, Montalescot G, Mahaffey KW, Kleiman NS, Goodman SG, Amine M, Angiolillo DJ, Becker RC, Chew DP, French WJ, Leisch F, Bhatt DL. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med 2009;361:2318-29. [Ref.ID 87366]
15. Cita con resumen
Califf RM, Harrington RA, Blazing MA. Premature release of data from clinical trials of ezetimibe. N Engl J Med 2009;361:712-7. [Ref.ID 86530]
16.Tiene citas relacionadas Cita con resumen
Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KH, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, for the PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-57. [Ref.ID 86474]
17.Tiene citas relacionadas
Becker RC, Moliterno DJ, Jennings LK, Pieper KS, Pei J, Niederman A, Ziada KM, Berman G, Strony J, Joseph D, Mahaffey KW, Van de Werf F, Veltri E, Harrington RA, for the TRA-PCI Investigators. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet 2009;373:919-28. [Ref.ID 85472]
18.Tiene citas relacionadas Cita con resumen
Harrington RA. Appropriate medical management and PCI. N Engl J Med 2007;357:1764. [Ref.ID 81340]
19.Tiene citas relacionadas
Harrington RA, Ohman EM. The enigma of drug-eluting stents. Hope, hype, humility, and advancing patient care. JAMA 2007;297:2028-30. [Ref.ID 80069]
Seleccionar todas
 
 1 a 20 de 34 siguiente >>